Eficacia y seguridad del aripiprazol en trastornos del espectro autista en población infanto-juvenil: revisión sistemática de la literatura
| Contribuinte(s) |
Barragan, Ana M. Vallejo Silva, Alexie |
|---|---|
| Data(s) |
01/02/2015
|
| Resumo |
Aunque han pasado cinco años desde su aprobación en Estados Unidos para el manejo de los Trastornos del Espectro Autista (TEA), en Colombia el uso de aripiprazol para esta indicación continúa siendo off-label. En este contexto, se ha propuesto la ejecución de una revisión sistemática de la literatura con el fin de conocer la eficacia y seguridad de esta estrategia terapéutica a la luz de la evidencia disponible en el manejo de niños y adolescentes con TEA Although there have been five years since its approval in the United States for the management of Autism Spectrum Disorders (ASD), in Colombia the use of aripiprazole for this indication remains off-label. In this context, we have proposed the implementation of a systematic literature review to determine the effectiveness and safety of this therapeutic strategy in the light of available evidence in the management of children and adolescents with ASD. |
| Formato |
application/pdf |
| Identificador | |
| Idioma(s) |
spa |
| Publicador |
Facultad de Medicina |
| Direitos |
info:eu-repo/semantics/openAccess |
| Fonte |
reponame:Repositorio Institucional EdocUR instname:Universidad del Rosario Reszka SS, Boyd BA, McBee M, Hume KA, Odom SL. Brief report: concurrent validity of autism symptom severity measures. Journal of autism and developmental disorders. 2014;44(2):466-70. Resolución 5521: Por la cual se define, aclara y actualiza integralmente el Plan Obligatorio de Salud (POS), 49019 (2013). Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. The Lancet. 2013;382(9904):1575-86. Duchan E, Patel DR. Epidemiology of autism spectrum disorders. Pediatric Clinics of North America. 2012;59(1):27-43. Posada-Villa JA, Aguilar-Gaxiola SA, Magaña CG, Gómez LC. Prevalencia de trastornos mentales y uso de servicios: resultados preliminares del Estudio Nacional de Salud Mental, Colombia, 2003. Revista Colombiana de Psiquiatría. 2004;33(3):241-62. Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. Journal of autism and developmental disorders. 2006;36(8):1101-14 Aman MG, Lam KS, Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. Journal of autism and developmental disorders. 2003;33(5):527-34. McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics. 2011;127(5):e1312-e21. Kanner L. Autistic disturbances of affective contact. Nervous child. 1943;2(3):217-50. Asperger H. Die „Autistischen Psychopathen” im Kindesalter. European Archives of Psychiatry and Clinical Neuroscience. 1944;117(1):76-136 Wing L. Asperger's syndrome: a clinical account. Psychological medicine. 1981;11(01):115-29. TEME |
| Palavras-Chave | #616.89 #Psiquiatría #Aripiprazol #Autismo #Aripiprazole, autism, systematic literature review |
| Tipo |
info:eu-repo/semantics/bachelorThesis info:eu-repo/semantics/acceptedVersion |
